Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.
You may also be interested in...
Deals Of The Week: Tire-Kicking Season Continues Full-Swing
As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.
Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups
Second-generation therapeutics are moving into the clinic following Celgene’s successful gamble on Abraxane. New nanobiotechs proliferate, but an industry burned by other promising technology revolutions remains somewhat wary of investing in early-stage firms.
Deerfield Management Opts For More Private Investment And A New Public Face
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.